

Pulmonary Enrollment Form

Fax: 909-284-9140
Phone: 909-266-0016

Urgent Request

PATIENT INFORMATION			PRESCRIBER INFORMA	TION			
	ving or send patient demogr a						
Patient Name			Prescriber Name				
Address			DEA				
Address 2			NPI				
City, State, Zip			Address				
City, State, ZipMobile Phone			City, State, Zip				
DOB Last Four of SS Gender			Phone Fax				
Language Preference			Contact Person				
Clinical Diagnosis: ple	ase fax or email relevant cli	nical notes, labs, te	sts, and previous medical his	story to expedite	prior authoriz	ation	
Diagnosis - Please include diagnosis name with ICD-10 code			Additional information	Therapy Restart	rapy New Reauthorization tart		
Weight		cm/in					
Allergies					 	-	
Lab Data						_	
Prior Therapies						_	
Concomitant Medications	3					_	
Additional Comments						_	
		PRESCRIPTIO	N INFORMATION				
Medication	Dose/Strength		Directions		Quantity	Refills	
□ Dupixent	□ 200mg/2ml PFS	□ Inject 400mg SQ followed by 400mg SQ every 2 weeks			(1111)		
	□ 200mg/2ml Pens	(Initial)					
	□ 300mg/2ml PFS	□ Inject 200mg SQ every 2 weeks (maintenance)					
	□ 300mg/2ml Pens	□ Inject 600mg SQ followed by 300mg SQ every 2 weeks					
]	(Initial)					
		□ Ìnject 300mg	SQ every 2 weeks (maintenance)				
				,			
□ Breztri	□ 1 inhaler	□ 2 puffs by mouth twice daily					
□ Tezspire	□ 210 mg PFS	□ Inject 210 mg SQ every 4 weeks					
•	_						
□ Fasenra	□ 30mg Pen	☐ Inject 30mg every 4 weeks for the first 3 doses (Initial)☐ Inject 30mg every 8 weeks (maintenance)					
	□ 30mg PFS						
□ Nucala	□ 100mg Auto Injector	☐ Inject 100mg SQ once every 4 weeks into the upper arm,					
	□ 100mg Syringe	thigh or abdomen					
] , ,						
□ Xolair	□ 150mg PFS						
	□ 75 mg PFS						
□ Other							
Ship to: Patient C	Office Other	•	Date:	Need by	Date		
any necessary forms on my beha that this pharmacy determines th	If as my authorized agent, including the re	ceipt of any required prior au urther authorize the pharma	d agent to secure coverage and initiate the uthorizations forms and the receipt and sub cy to forward this information and any relat	mission of patient tab valu	ues and other patient	data, in the event	
□ Product Substitution perm	itted □ Dispense as Written						
Prescriber's Signature:		Date:	Date:				
CONFIDENTIALITY STATEMENT: This communication is not the intended recip	communication is intended for use of the individual pient or the employee or agent responsible for deliv	or entity to which it is addressed a very of the communication, you are	nd may contain information that is privileged, confidence hereby notified that any dissemination distribution,	dential, and exempt from disclo , or copying of the communicat	sure under applicable law ion is strictly prohibited. I	If the reader of this f you have received this	